Fluocinolone acetonide (0.1%) treatment in oral lichen planus patients did not affect salivary lactoferrin levels and Candida carriage

Not Applicable

Completed

• Conditions: Increase of salivary Lf and oral Candida

• Registration Number: TCTR20200723002
• Lead Sponsor: Faculty of Dentistry, Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2018-04-23
• Study Start: 2020-07-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Oral lichen planus patients (OLP) with severity evaluated according to Thongprasom scoring system as score 3, 4 or 5.
2. OLP patients have not used a topical steroid before participating in this study.
3. OLP patients are treated with 0.1% FAO applied 3 times daily for 3 months during the investigation.
4. Participants have no signs of oral candidiasis at the beginning of the study.
5. Participants have no history of treatment with chemotherapy or radiotherapy.
6. Participants have no signs of dry mouth.
7. Participants have no history of any disease or medical condition predisposing them to oral candidiasis.
8. Participants have no history of taking antifungal agents, using an antiseptic mouthwash, or smoking for at least 1 month.

Exclusion Criteria

1. Participants use antifungal agents during the investigation time.
2. To change in type or preparation of topical steroid treatment during the investigation time.
3. Participants would like to withdraw from the research project.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Salivary lactoferrin at the baseline and 3 months after treatment with topical steroid enzyme-linked immunosorbent assay (ELISA)

Secondary Outcome Measures

Name	Time	Method
Oral Candida species at the baseline and 3 months after treatment with topical steroid Salivary culture